Mark Henderson, Science Editor
Win VIP tickets
Stem-cell therapies for diseases such as Parkinson’s and diabetes could become illegal under embryo research laws planned by the Government, The Times has learnt.
The Human Fertilisation and Embryology Bill currently passing through Parliament could prevent patients from receiving potentially life-saving treatments based on embryonic stem cells, because it does not permit regulators to license them for therapeutic use.
Embryonic stem cells are powerful master cells found in human embryos, which can grow into any type of tissue. They hold great promise for treating conditions such as diabetes, Parkinson’s and spinal paralysis.
While the Bill allows scientists to obtain licences to use these cells for medical experiments, it contains no mechanism for approving treatments should this research prove successful.
Leading scientists, lawyers and MPs have warned ministers that unless the legislation is amended when it reaches the House of Commons in late spring, it could stop patients from benefiting from the very medical research the Government is encouraging.
The problem has arisen because the Bill allows the Human Fertilisation and Embryology Authority to license the use of human embryos only for medical research or treatment of infertility. This does not matter at present, as no embryonic stem-cell therapies are ready to be given to patients, and it would not affect clinical trials because these would be classified as research.
Once techniques move beyond an experimental stage, however, doctors would not be allowed to give them to patients without fresh primary legislation, scientists and lawyers say.
This would significantly delay patients’ access to therapies that are the goal of stem-cell research, and would make it harder for scientists to raise funds from the biotechnology industry.
Professor Robin Lovell-Badge, a stem-cell scientist at the National Institute for Medical Research in London, said: “They have not thought the whole picture through properly. Once you get the protocol right, and you want to grow embryonic stem cells to treat patients, that is no longer research.”
James Lawford Davies, a solicitor with Clifford Chance who specialises in embryology law, said: “There is at the very least a grey area here. Without proper provisions you can guarantee that people who object to embryo research are going to try a legal challenge.”
Evan Harris, the Liberal Democrat science spokesman, said: “One of the goals of embryonic stem-cell research is to provide therapies, but as the Bill stands it may not be possible to license these.”
The Government rejected amendments tabled in the House of Lords that would have allowed the HFEA to include treatment in the terms of its licences, saying that the definition of research would be sufficiently broad.
A spokeswoman for the Department of Health said: “On the basis of [legal] advice, the Government is of the view that the currently anticipated licensing framework would in fact allow the derivation of embryonic stem cells, and the development of those cells into a therapeutic product without the need for amendment of the Bill.”
The Times understands, however, that the Government is now reconsidering its position, and may table an amendment in the Commons to address scientists’ concerns.
The Government also came under pressure yesterday to allow Labour MPs a free vote on the entire Bill, after MPs who support more liberal legislation said their opponents should be free to vote with their consciences.
An early day motion calling for a free vote, tabled by David Burrowes, a Conservative MP, has been signed by 70 MPs. They include advocates of embryo research such as Dr Harris, Robert Key, a former Tory science spokesman, and Phil Willis, who chairs the Innovation, Skills, Science and Universities Select Committee, as well as opponents such as Mr Burrowes and Ann Widdecombe.
Last week more than 100 academics with different opinions on the legislation wrote to The Times to demand a fully free vote, as was granted when the present laws were passed in 1990.
Dr Harris said: “Individual MPs should be entitled to vote with their conscience on clear conscience issues such as these.”
The big issues
Three issues on which the Government has backed down
Merged regulators
Original Human Tissue and Embryos Bill proposed merger between embryo research
and IVF watchdog and human tissue regulator. Plan dropped and Bill renamed
after criticism from scientists, MPs and peers
Hybrid embryos
Draft Bill would have banned research on embryos created by combining human
and animal tissue, which scientists want to use to make laboratory models of
disease. These will now be permitted
Consent
Legislation would have banned scientists using tissue for cloning when donors
had not given explicit consent. This will now not be applied
retrospectively, after researchers said this would deny them access to
important cell libraries that were donated for general medical research
And three more on which it might
Treatment licences
Bill does not provide for licences to be issued for therapies based on
embryonic stem cells. Ministers considering revising it to permit this
Artificial sperm and eggs
Present Bill bans the use of sperm or eggs made from stem cells in fertility
treatment. MPs will table an amendment that would give Parliament the right
to approve this at a later date without primary legislation
Children
Existing wording means parents cannot consent to use of their children’s cells
in cloning experiments, even when they would die before reaching the age of
majority. Government has accepted the case for revising this, and lawyers
are drafting a clause that would be compatible with the Human Rights Act
Source: Times database

Win a luxury weekend to Newcastle and its neighbour Gateshead, find out more here
Risk, resilience and embracing new technology
Industry sectors news at a glance. Interactive heatmap, video and podcast
Discover the power of collective thinking. Submit a solution and be in with a chance to win a Media Hub Home Entertainment System
The inside track on current trends in the charity, not for profit and social enterprise sectors
Everything the Business Traveller needs to know to make a better trip
Make the most of the summer and enter our fabulous photographic competition, you could win a £5000 holiday
Corsica is an island of beauty and contrast, an ideal holiday destination
Enjoy further reading from Travel to Fashion, Business to Sport, discover more
Shortcuts to help you find sections and articles
The clever way to lease a new car is with Car leasing made simple™
2009
per month on 36-month
Personal Contract Hire (PCH)
2008
42850
Car Insurance
£23,093 - £56,211
The Office for National Statistics
Newport, South Wales
£60,000
The Environment Agency
Bristol
Up to £90K
Boots
Midlands
OTE £85k
Credit Protection Association
Nationwide Opportunities
Completely London
Luxury Condo's in Manhattan with NYC views
The best new homes in Wimbledon?
Nationwide
Fabulous Cruise And Cruise & Stay Offers Including Virgin Atlantic Flights Prices Start From Only £699pp!
Last Minute Cruise And Cruise & Stay Offers. Med From £499pp, Caribbean From £699pp!
5 star quality at a 3 star price.
8 fabulous Canadian cities ...you won’t find cheaper
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths | Subscriptions | E-paper
News International associated websites: Globrix Property Search | Property Finder | Milkround
Copyright 2009 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.